Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) is expected to be issuing its Q3 2025 quarterly earnings data before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.
Palatin Technologies Stock Performance
Shares of PTN stock opened at $0.10 on Tuesday. The company has a market capitalization of $2.49 million, a PE ratio of -0.06 and a beta of 0.87. Palatin Technologies has a 52-week low of $0.09 and a 52-week high of $2.13. The business’s fifty day moving average is $0.38 and its 200 day moving average is $0.86.
Analyst Upgrades and Downgrades
Separately, HC Wainwright lowered their price target on Palatin Technologies from $17.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, February 13th.
About Palatin Technologies
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
See Also
- Five stocks we like better than Palatin Technologies
- What to Know About Investing in Penny Stocks
- UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?
- What Are Treasury Bonds?
- What Ray Dalio’s Latest Moves Tell Investors
- What Does a Stock Split Mean?
- Amazon: Why May Is the Last Month to Get the Stock at a Discount
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
